Gapping up
In reaction to strong earnings/guidance: SQNM +23.5%, MITK +15.5%, OLED +14.9%, UBNT +14.7%, (also upgraded to Outperform from Neutral at Wedbush) AIRM +12.2%, ENOC +11.6%, ARAY +10.1%, ( Two papers from a large multi-site study further demonstrate efficacy and quality of life benefits for prostate cancer patients treated with co's CyberKnife System), HALO +9.9%, LCI +9.5%, ADEP +9%, ABTL +8.6%, MDRX +7.9%, FEYE +6.7%, ACET +6.6%, ARNA +6.4%, NKTR +6.2%, PTIX +6.1%, GPS +6%, PCYC +4%, GERN +3.8%, CPST +3.6%, NVAX +3.6%, SSTK +3.5%, XON +3.2%, ENSG +3.2%, CLNE +3.1%, GRPN +2.6%, CYTX +2.5%, VVC +2.5%, UEPS +2.3%, ATW +2.2%, III +2%, SGMS +1.8%, TEF +1.8%, BONE +1.6%, NVDA +1.6%, PCLN +1.6%, NOG +1.3%.
M&A news: SNTS +37.9% (Santarus to be acquired by Salix Pharmaceuticals (SLXP) for $32 per share), SLXP +11.5%.
Other news: XONE +4% (announced it will open its seventh production service center), ENSG +3.2% (announced plan to separate its healthcare business and its real estate business into two separate and independent publicly-traded cos; adopted stockholder rights plan), OCZ +2.5% ( resolves remaining shareholder derivative legal matters), OXBT +2.2% (receives $6 mln in net proceeds from warrant exercises), LUV +1% (reports co granted permission to file brief related to US Airways (LCC)/American (AAMRQ) take off and landing slots).
Analyst comments: AMRN +12.1% (upgraded to Buy from Neutral at Citigroup), AHL +9% (upgraded to Buy from Neutral at UBS), SUNE +6.6% (Hearing positive comments at Citigroup), BTU +1.8% (upgraded to Buy from Neutral at Goldman), LYG +1.3% (upgraded to Buy from Hold at Investec)